for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Petmed Express Inc

PETS.OQ

Latest Trade

17.16USD

Change

0.18(+1.06%)

Volume

367,209

Today's Range

17.03

 - 

17.51

52 Week Range

15.00

 - 

37.27

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.98
Open
17.03
Volume
367,209
3M AVG Volume
18.38
Today's High
17.51
Today's Low
17.03
52 Week High
37.27
52 Week Low
15.00
Shares Out (MIL)
20.17
Market Cap (MIL)
342.57
Forward P/E
16.20
Dividend (Yield %)
6.36

Next Event

Q2 2019 Petmed Express Inc Earnings Release

Latest Developments

More

Petmed Express Q1 Earnings Per Share $0.26

Petmed Express Inc Reports Q4 EPS $0.32

Petmed Express Reports Q3 Earnings Per Share Of $0.38

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Petmed Express Inc

PetMed Express, Inc. (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies. Its products include brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution and Rimadyl. It also offers additional pet supplies for sale on its Website, which are drop shipped to its customers by third parties. These pet supplies include food, beds, crates, stairs, strollers and other pet supplies. Its products included Non-Prescription Medications (Over the Counter (OTC)) and supplies, and Prescription Medications (Rx). Its customers are located in California, Florida, Texas, New York, Virginia and Georgia, among others.

Industry

Retail (Drugs)

Contact Info

420 S Congress Ave

+1.561.4264444

https://www.1800petmeds.com/

Executive Leadership

Robert C. Schweitzer

Independent Chairman of the Board

Menderes Akdag

President, Chief Executive Officer, Director

Bruce S. Rosenbloom

Chief Financial Officer, Treasurer

Leslie C.G. Campbell

Independent Director

Frank J. Formica

Independent Director

Key Stats

2.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.3K

2019

0.3K

2020(E)

0.3K
EPS (USD)

2017

1.170

2018

1.820

2019

1.840

2020(E)

1.048
Price To Earnings (TTM)
11.39
Price To Sales (TTM)
1.24
Price To Book (MRQ)
2.76
Price To Cash Flow (TTM)
10.46
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
24.47
Return on Equity (TTM)
20.50

Latest News

BRIEF-PetMed Express Reports Q4 Earnings Per Share Of $0.50

* PETMED EXPRESS, INC. D/B/A 1-800-PETMEDS ANNOUNCES RECORD EARNINGS FOR ITS 4TH FISCAL QUARTER AND ITS QUARTERLY DIVIDEND OF $0.25 PER SHARE

BRIEF-‍Plaintiffs Dismiss Shareholders Claims Dated August And September 2017

* PETMED EXPRESS - PLAINTIFFS INVESTIGATED SHAREHOLDERS CLAIMS DATED AUGUST AND SEPT 2017, VOLUNTARILY DISMISSED CONSOLIDATED LAWSUIT - SEC FILING Source text for Eikon: [http://bit.ly/2Dyf1G6] Further company coverage:

BRIEF-PetMed Express Reports Q3 EPS OF $0.44

* PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES ITS THIRD QUARTER FINANCIAL RESULTS AND INCREASED ITS QUARTERLY DIVIDEND BY 25% TO $0.25 PER SHARE

BRIEF-Petmed Express Q2 earnings per share $0.43

* Petmed Express D/B/A 1-800-petmeds announces record second quarter financial results

PetMed CFO says allegations of marketing to opioid addicts are 'bogus'

A short seller's allegations that PetMed Express markets pet medicine to human opioid addicts are "bogus," PetMed Chief Financial Officer Bruce Rosenbloom told Reuters on Wednesday.

BRIEF-PetMed express D/B/A 1-800-PetMeds announces record first quarter financial results

* Q1 earnings per share view $0.38 -- Thomson Reuters I/B/E/S

BRIEF-Petmed Express reports Q4 earnings per share $0.37

* Petmed Express Inc D/B/A 1-800-petmeds announces its financial results for fiscal 2017 and its quarterly dividend raised to $0.20 per share

BRIEF-Petmed Express Q3 EPS $0.24

* Petmed express d/b/a 1-800-petmeds announces its third quarter financial results and its $0.19 per share quarterly dividend

BRIEF-PetMed express Q2 sales $60.8 mln versus I/B/E/S view $58.7 mln

* Petmed express D/B/A 1-800-PetMeds announces its second quarter financial results and its $0.19 per share quarterly dividend

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up